NCT00003245已完成2 期
Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.
详细描述
OBJECTIVES:
- Determine the objective response rate and toxicity of irinotecan when administered to patients with recurrent or refractory non-Hodgkin's lymphoma.
OUTLINE: Patients are stratified by disease category (aggressive vs indolent vs mantle cell lymphoma). Patients with aggressive and indolent lymphoma are further stratified as to being refractory (no complete response (CR) or partial response (PR) to initial therapy) vs recurrent (CR or PR to initial therapy); i.e, the following subcategories are used:
- Stratum I:Refractory aggressive non-Hodgkin's lymphoma (NHL)
- Stratum II:Recurrent aggressive NHL
- Stratum III: Refractory indolent NHL
- Stratum IV: Recurrent indolent NHL
- Stratum V: Mantle cell NHL All patients receive irinotecan intravenously every 21 days. Patients achieving CR or PR receive 6 courses. Patients may receive bone marrow transplantation after at least 2 courses.
Patients are followed every 3 months for survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving AnticonvulsantsUnspecified Childhood Solid Tumor, Protocol SpecificNCT00008424Children's Oncology Group7
已完成
2 期
Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCarcinoma of Unknown PrimaryNeuroendocrine CarcinomaNeuroendocrine Carcinoma of the SkinNCT00004922Memorial Sloan Kettering Cancer Center
已完成
2 期
Irinotecan in Treating Patients With Refractory Metastatic Breast CancerBreast CancerNCT00003351Alliance for Clinical Trials in Oncology104
已完成
1 期
Irinotecan in Treating Patients With Progressive or Recurrent Malignant GliomaBrain and Central Nervous System TumorsNCT00003616Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
2 期
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung CancerLung CancerNCT00003900Alliance for Clinical Trials in Oncology48